<DOC>
	<DOCNO>NCT02126384</DOCNO>
	<brief_summary>The purpose study determine B lymphocytes subset responsible production IgM , IgG2 IgA anti-pneumococcal capsular polysaccharide vaccination 23-valent pneumococcal polysaccharide vaccine .</brief_summary>
	<brief_title>Identifocation B Cell Subsets Responsible Anti-pneumococcal Response</brief_title>
	<detailed_description>The aim study identify specific B cell subset ( ) is/are responsible production protective IgM , IgG2 IgA anti-pneumococcal capsular polysaccharide ( capPS ) response immunization healthy individual Pneumovax , prototypical T-independent type 2 vaccine . In word , B cell IgM , G2 A-secreting plasma cell derive ? To address question , take advantage unique Ig heavy chain VDJ signature express B cell clone strategy rely search clonal filiation plasmablast ( PB ) /plasma cell ( PC ) different B cell subpopulation . Therefore , healthy individual vaccinate Pneumovax , blood sample collect day 0 , 7 , 14 , 28 56 . Starting blood sample , different B cell subset ( particular IgM+IgD+CD27+ switch memory IgM−IgD−CD27+ B cell ) PB/PC peak day 7 vaccination isolate cell sort . CapPS-secreting PB specifically isolate , investigator assume represent majority isolate PB/PC peak response . Thus , day 7-PB/PC sort bulk single cell 96-well PCR plate . RNA extract bulk sort PB/PC , VDJ-µ , -alpha -gamma Ig transcript amplify RT-PCR analyze H-CDR spectratyping method order identify sequence dominant VDJ signatures probably correspond anti-capPS-secreting cell . In parallel , PB/PC single cell , Ig heavy correspond Ig light chain gene transcript amplify nested RT-PCR , sequence , provide heavy chain contains dominant VDJ signature , clone eukaryotic expression vector produce monoclonal human Abs . The recombinant antibody test reactivity capPS vaccine ELISA . When VDJ signatures capPS validate , powerful molecular tool , investigator look presence signature VDJ-specific PCR cDNA prepare different B cell subset .</detailed_description>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>male age 18 40 documented primary immunodeficiency splenectomy functional/congenital asplenia , pneumococcal infection within last 5 year enrolment research protocol vaccination 23valent pneumococcal polysaccharide vaccine 7 13valent conjugatepolysaccharide vaccine within last 5 year enrolment research protocol vaccination within 1 month enrolment research protocol fever , current antibiotic treatment chronic inflammatory disease immunosuppressive treatment hyperresponsiveness one component Pneumovax vaccine</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Immunology</keyword>
	<keyword>human</keyword>
	<keyword>B-lymphocytes subset</keyword>
	<keyword>Antibody-Producing Cells</keyword>
	<keyword>23 valent pneumococcal capsular polysaccharide vaccine</keyword>
</DOC>